Influence of noradrenaline denervation on MPTP-induced deficits in mice Authors
First Online: 16 December 2005 Received: 06 June 2005 Accepted: 09 October 2005 DOI:
Cite this article as: Archer, T. & Fredriksson, A. J Neural Transm (2006) 113: 1119. doi:10.1007/s00702-005-0402-5 Summary.
C57/BL6 mice were administered either DSP4 (50 mg/kg, s.c., 30 min after injection of zimeldine, 20 mg/kg, s.c.) or vehicle (saline) at 63 days of age. Three weeks later, one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered MPTP (2 × 40 mg/kg, s.c., 24 hours between injections; the High dose groups), one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered MPTP (2 × 20 mg/kg, s.c., 24 hours between injections; the Low dose groups), and one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered vehicle. Three weeks later, all six groups were tested in motor activity test chambers, followed by injections of L-Dopa (20 mg/kg, s.c.), and then tested over a further 360 min in the activity test chambers. It was found that pretreatment with the selective NA neurotoxin, DSP4, deteriorated markedly the dose-dependent motor activity deficits observed in the vehicle pretreated MPTP treated mice. These ‘ultra-deficits’ in the spontaneous motor behaviour of MPTP-treated mice were observed over all three parameters: locomotion, rearing and total activity, and were restricted to the 1
st and 2 nd 20-min periods. Administration of L-Dopa (20 mg/kg) following the 60-min testing of spontaneous behaviour restored the motor activity of Vehicle + MPTP treated mice (neither the Vehicle + MPTP-Low nor the Vehicle + MPTP-High groups differed from the Vehicle–Vehicle group, here) but failed to do so in the DSP4 pretreated mice. Here, a dose-dependent deficit of L-Dopa-induced motor activity (over all three parameters) was obtained thereby offering further evidence of an ‘ultra-deficit’ of function due to previous denervation of the NA terminals. The present findings support the notion that severe damage to the locus coeruleus noradrenergic system, through systemic DSP4, disrupts the facilitatory influence on the nigrostriatal DA system, and interferes with the ability of the nigrostriatal pathway to compensate for or recover from marked injury, MPTP treatment. Keywords: DSP4, MPTP, vehicle, motor deficits, locomotion, rearing, total activity, L-Dopa, restoration, attenuation, DA, NA, C57/BL6 mice, movement disorder, PD. References Andén, N-E, Grabowska, M 1976 Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain Eur J Pharmacol 39 275 282 PubMed CrossRef Archer, T 1982 Serotonin and fear retention in the rat J Comp Physiol Psychol 96 491 516 PubMed CrossRef Archer, T, Fredriksson, A 2000 Effects of clonidine and adrenoceptor antagonists on motor activity in DSP4-treated mice. I. Dose, time- and parameter-dependency Neurotox Res 1 235 247 PubMed Archer, T, Fredriksson, A 2001 Effects of α-adrenoceptor agonists in chronic morphine administered DSP4-treated rats: evidence for functional cross-sensitization Neurotox Res 3 411 432 PubMed Archer, T, Fredriksson, A 2003 An antihypokinesic action of α2-adrenoceptors upon MPTP-induced behaviour deficits in mice J Neural Transm 110 183 200 PubMed CrossRef Archer, T, Ögren, S-O, Johansson, G, Ross, SB 1982 DSP4-induced two-way active avoidance impairment: involvement of central and not peripheral noradrenaline depletion Psychopharmacology 76 303 309 PubMed CrossRef Archer, T, Mohammed, AK, Ross, SB, Söderberg, U 1983 T-maze learning, spontaneous activity and food intake recovery following systemic administration of the noradrenaline neurotoxin, DSP4 Pharmacol Biochem Behav 19 121 130 PubMed CrossRef Archer, T, Jonsson, G, Ross, SB 1984 A parametric study of the effects of the noradrenaline neurotoxin DSP4 on avoidance acquisition and noradrenaline neurons in the CNS of the rat Br J Pharmacol 82 249 257 PubMed Archer, T, Jonsson, G, Ross, SB 1985 Active and passive avoidance following the administration of systemic DSP4, xylamine, or p-chloroamphetamine Behav Neural Biol 43 238 249 PubMed CrossRef Archer, T, Fredriksson, A, Jonsson, G, Lewander, T, Mohammed, AK, Ross, SB, Soderberg, U 1986a Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat Psychopharmacology 88 141 146 CrossRef Archer, T, Jonsson, G, Minor, BG, Post, C 1986b Noradrenergic-serotonergic interactions and nociception in the rat Eur J Pharmacol 120 295 307 CrossRef Berlan, M, Rascol, O, et al. 1989 Alpha 2-adrenergic sensitivity in Parkinson’s disease Clin Neuropharmacol 12 138 144 PubMed Berridge, CW, Dunn, AJ 1990 DSP-4-induced depletion of brain norepinephrine produces opposite effects on exploratory behaviour 3 and 14 days after treatment Psychopharmacology 100 504 508 PubMed CrossRef Dolphin, AC, Jenner, P, Marsden, CD 1976a The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or α-methyl-p-tyrosine pre-treated mice Pharmacol Biochem Behav 4 661 670 CrossRef Dolphin, AC, Jenner, P, Marsden, CD 1976b Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity Pharmacol Biochem Behav 5 431 439 CrossRef Dooley, DJ, Bittiger, H, Hauser, KL, Bischoff, SL, Waldmeier, PC 1983a Alteration of central alpha 2- and beta-adrenergic receptors in the rat after DSP4, a selective noradrenergic neurotoxin Neuroscience 9 889 898 CrossRef Dooley, DJ, Mogilnicka, E, Delini-Stula, A, Waechter, F, Truog, A, Wood, J 1983b Functional supersensitivity to adrenergic agonists in the rat after DSP-4, a selective noradrenergic neurotoxin Psychopharmacology 81 1 5 CrossRef Fornai, F, Bassi, L, Torracca, MT, Alessandri, MG, Scalori, V, Corsini, GU 1996 Region- and neurotransmitter-dependent species and strain differences in DSP4-induced monoamine depletion in rodents Neurodegeneration 5 241 249 PubMed CrossRef Fornai, F, Alessandri, MG, Torracca, MT, Bassi, L, Corsini, GU 1997 Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions J Pharmacol Exp Ther 283 100 107 PubMed Fredriksson, A, Archer, T 1994 MPTP-induced behavioural and biochemical deficits: a parametric analysis J Neural Transm (PD Sect) 7 123 132 CrossRef Fredriksson, A, Archer, T 2000 Effects of clonidine and α-adrenoceptor antagonists on motor activity in DSP4-treated mice. II. Interactions with apomorphine Neurotox Res 1 249 259 PubMed Fredriksson, A, Archer, T 2003 Effect of postnatal iron administration on MPTP-induced behavioural deficits and neurotoxicity: behavioural enhancement by L-Dopa-MK-801 co-administration Behav Brain Res 139 31 46 PubMed CrossRef Fredriksson, A, Palomo, T, Chase, TN, Archer, T 1999a Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists J Neural Transm 106 283 300 CrossRef Fredriksson, A, Plaznik, A, Sundström, E, Jonsson, G, Archer, T 1990 MPTP-induced hypoactivity in mice: reversal by L-Dopa Pharmacol Toxicol 67 295 301 PubMed CrossRef Fredriksson, A, Schroder, N, Eriksson, P, Izquierdo, I, Archer, T 2001 Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits Parkinsonism Rel Disord 7 97 105 CrossRef Glowinski, J, Iversen, LL 1966 Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain J Neurochem 13 655 669 PubMed Goldstein, M, Engel, J, et al. 1983 Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoceptor agonists J Neural Transm 18 257 263 Heal, DJ, Butler, SA, Prow, MR, Buckett, WR 1993 Quantification of alpha 2-adrenoceptors in rat brain after short-term DSP-4 lesioning Eur J Pharmacol 249 37 41 PubMed CrossRef Heikkila, RE, Sieber, B-A, Manzino, L, Sonsalla, PK 1989 Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse Mol Chem Neuropathol 10 171 183 PubMed CrossRef Henry, B, Crossman, AR, et al. 1998 Characterisation of enhanced behavioural responses to L-DOPA following repeated administration in the 6-hydroxydopamine model of Parkinson’s disease Exp Neurol 151 334 342 PubMed CrossRef Jonsson, G, Hallman, H 1982 Response of central monoamine neurons following an early neurotoxic lesion Bibl Anat 23 76 92 PubMed Jonsson, G, Hallman, H, Ponzio, F, Ross, SB 1981 DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) – a useful denervation tool for central and peripheral noradrenaline neurons Eur J Pharmacol 72 173 188 PubMed CrossRef Jonsson, G, Hallman, H, Sundström, E 1982 Effects of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenaline neurons in the rat Neuroscience 7 2895 2907 PubMed CrossRef Kirk, R 1995Experimental design: procedures for the behavioural sciences Brooks/Cole Belmont, CA Langston, JW 1985 MPTP neurotoxicity: an overview and characterization of phases of toxicity Life Sci 36 201 206 PubMed CrossRef Latigan, AJ, Marien, MR, Colpaert, FC 1992 Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study Life Sci 50 995 999 CrossRef Marien, MR, Briley, M, Colpaert, FC 1993 Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice Eur J Pharmacol 236 487 489 PubMed CrossRef Marien, MR, Colpaert, FC, Rosenquist, AC 2004 Noradrenergic mechanisms in neurodegenerative diseases: a theory Brain Res Rev 45 38 78 PubMed CrossRef Nishi, K, Kondo, T, Narabayashi, H 1991 Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa Neurosci Lett 123 244 247 PubMed CrossRef Persson, T, Waldeck, B 1970 Further studies on the possible interaction between dopamine and noradrenaline containing neurons in the brain Eur J Pharmacol 11 315 320 PubMed CrossRef Ponzio, F, Hallman, H, Jonsson, G 1981 Noradrenaline and dopamine interaction in rat brain during development Med Biol 59 161 169 PubMed Post, C, Persson, ML, Archer, T, Minor, BG, Danysz, W, Sundström, E 1987 Increased antinociception by alpha-adrenoceptor drugs after spinal cord noradrenaline depletion Eur J Pharmacol 137 107 116 PubMed CrossRef Riekkinen, M, Kejonen, K, et al. 1998 Reduction of noradrenaline impairs attention and dopamine depletion slows response in Parkinson’s disease Eur J Neurosci 10 1429 1435 PubMed CrossRef Ross, SB 1976 Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart Br J Pharmacol 58 521 527 PubMed Ross, SB, Renyi, L 1976 On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on the active uptake of noradrenaline J Pharmacol Pharmac 28 458 459 Shoulson, Y, Chase, TN 1976 Clonidine and the antiparkinsonian response to L-Dopa or piribedil Neuropharmacology 15 25 27 PubMed CrossRef Sonsalla, PK, Heikkila, RE 1986 The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice Eur J Pharmacol 129 339 345 PubMed CrossRef Sundström, E, Fredriksson, A, Archer, T 1990 Chronic neurochemical and behavioural changes in MPTP-lesioned C57 Bl/6 mice: a model for Parkinson’s disease Brain Res 528 181 188 PubMed CrossRef Tarsy, D, Parkes, JD, et al. 1975 Clonidine in Parkinson’s disease Arch Neurol 32 134 136 PubMed